iCo Therapeutics (iCo Therapeutics) EV-to-Revenue : (As of May. 03, 2024)

View and export this data going back to 2009. Start your Free Trial

What is iCo Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, iCo Therapeutics's enterprise value is $8.89 Mil. iCo Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2021 was $0.00 Mil. Therefore, iCo Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for iCo Therapeutics's EV-to-Revenue or its related term are showing as below:

During the past 13 years, the highest EV-to-Revenue of iCo Therapeutics was 4782.89. The lowest was -128.93. And the median was 196.36.

ICOTF's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.07
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-03), iCo Therapeutics's stock price is $1.1693. iCo Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2021 was $0.00. Therefore, iCo Therapeutics's PS Ratio for today is .

iCo Therapeutics EV-to-Revenue Historical Data

The historical data trend for iCo Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iCo Therapeutics EV-to-Revenue Chart

iCo Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

EV-to-Revenue

Get a 7-Day Free Trial

iCo Therapeutics Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
EV-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of iCo Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, iCo Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iCo Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, iCo Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where iCo Therapeutics's EV-to-Revenue falls into.

iCo Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

iCo Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	8.893	/	0
	=

iCo Therapeutics's current Enterprise Value is $8.89 Mil.
iCo Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

iCo Therapeutics (GREY:ICOTF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

iCo Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.1693	/	0
	=

iCo Therapeutics's share price for today is $1.1693.
iCo Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

iCo Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of iCo Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

iCo Therapeutics (iCo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iCo Therapeutics Inc (GREY:ICOTF) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

777 Hornby Street, 6th Floor, Vancouver, BC, CAN, V6Z 1S4

Website

http://www.icotherapeutics.com

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between the cells of the immune system. Geographically, it operates in Canada and Australia.

iCo Therapeutics (iCo Therapeutics) Headlines

No Headlines